Edit
Bolt Biotherapeutics, Inc.
https://boltbio.com/?portfolioCats=34,23,29,35,22,24,30,25,28,31#new_tabBolt Biotherapeutics, Inc., based in the San Francisco Bay Area, is a publicly-traded biotechnology company developing Boltbody™ Immune-stimulating Antibody Conjugates (ISAC), a new class of immuno-oncology therapeutics that have eliminated tumors following systemic administration in preclinical studies and results in the development of immunological memory, which may lead to more durable clinical responses for patients. Bolt’s technology is appropriate for a broad spectrum of antibodies targeting tumor antigens expressed on all types of cancer and therefore applicable to many types of patients, including those who are refractory to the current generation of checkpoint inhibitors. The company is led by a team with extensive oncology drug discovery and development experience. Bolt was founded by Dr. Ed Engleman, and its platform is based on technology exclusively licensed from Stanford University. The company is financed by world-class investors including Novo Holdings, Pivotal bioVenture Partners, Vivo Capital and Nan Fung Life Sciences. For more information about Bolt Biotherapeutics, please visit www.boltbio.com.
Location: United States, California, Redwood City
Member count: 51-200
Total raised: $377.5M
Founded date: 2015
Investors 4
| Date | Name | Website |
| - | RA Capital... | racap.com |
| - | Sofinnova ... | sofinnova.... |
| - | NFLS - Piv... | pivotalbio... |
| - | Vivo Capit... | vivocapita... |
Funding Rounds 3
| Date | Series | Amount | Investors | Deal News |
| 05.02.2021 | IPO | $230M | - | pitchbook.... |
| 02.07.2020 | Series C | $93.5M | - | finsmes.co... |
| 05.02.2019 | Series B | $54M | - | finsmes.co... |
Mentions in press and media 18
| Date | Title | Description | Category | Author | Source |
| 19.11.2021 | Bolt Bioth... | REDWOOD CITY, Calif., Nov. 19,... | - | - | marketscre... |
| 10.11.2021 | Bolt Bioth... | Bolt Biotherapeutics Reports T... | - | - | marketscre... |
| 09.11.2021 | Bolt Bioth... | –BDC-1001 Phase 1/2 dose-escal... | - | - | marketscre... |
| 12.08.2021 | Bolt Bioth... | Bolt Biotherapeutics Reports S... | - | - | marketscre... |
| 12.08.2021 | Bolt Bioth... | – BDC-1001 Phase 1/2 trial in ... | - | - | marketscre... |
| 08.02.2021 | Bolt Bioth... | Bolt Biotherapeutics, a develo... | - | - | pitchbook.... |
| 05.02.2021 | Bolt Bioth... | - | - | - | vivocapita... |
| 03.02.2021 | Bolt Bioth... | Bolt Biotherapeutics has set t... | - | - | pitchbook.... |
| 05.01.2021 | Bolt Bioth... | REDWOOD CITY, Calif., Jan. 5... | - | - | prnewswire... |
| 07.12.2020 | Data Publi... | REDWOOD CITY, Calif., Dec. 7... | - | - | prnewswire... |
Show more